Catalent (CTLT) Competitors

BioNTech (NASDAQ:BNTX) and Catalent (NYSE:CTLT) are both large-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, earnings, institutional ownership, risk, community ranking, media sentiment, valuation, profitability and analyst recommendations.

Which has more risk and volatility, BNTX or CTLT?

BioNTech has a beta of 0.26, meaning that its stock price is 74% less volatile than the S&P 500. Comparatively, Catalent has a beta of 1.16, meaning that its stock price is 16% more volatile than the S&P 500.

Do insiders and institutionals hold more shares of BNTX or CTLT?

15.5% of BioNTech shares are held by institutional investors. 19.2% of BioNTech shares are held by insiders. Comparatively, 0.3% of Catalent shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Which has preferable valuation & earnings, BNTX or CTLT?

BioNTech has higher earnings, but lower revenue than Catalent. BioNTech is trading at a lower price-to-earnings ratio than Catalent, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioNTech	$3.04B	8.46	$1.01B	-$2.10	-51.50
Catalent	$4.38B	2.48	-$1.04B	-$5.49	-10.91

Does the media prefer BNTX or CTLT?

In the previous week, BioNTech had 20 more articles in the media than Catalent. MarketBeat recorded 37 mentions for BioNTech and 17 mentions for Catalent. BioNTech's average media sentiment score of 0.38 beat Catalent's score of 0.15 indicating that BioNTech is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioNTech	12 Very Positive mention(s)	3 Positive mention(s)	11 Neutral mention(s)	6 Negative mention(s)	0 Very Negative mention(s)	Neutral
Catalent	5 Very Positive mention(s)	1 Positive mention(s)	7 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral

Does the MarketBeat Community prefer BNTX or CTLT?

Catalent received 509 more outperform votes than BioNTech when rated by MarketBeat users. Likewise, 57.92% of users gave Catalent an outperform vote while only 44.56% of users gave BioNTech an outperform vote.

Company	Underperform	Outperform
BioNTech	Outperform Votes 131 44.56%	Underperform Votes 163 55.44%
Catalent	Outperform Votes 640 57.92%	Underperform Votes 465 42.08%

Is BNTX or CTLT more profitable?

BioNTech has a net margin of -18.69% compared to Catalent's net margin of -22.72%. Catalent's return on equity of -0.56% beat BioNTech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioNTech	-18.69%	-2.54%	-2.24%
Catalent	-22.72%	-0.56%	-0.21%

Do analysts rate BNTX or CTLT?

BioNTech currently has a consensus target price of $134.69, suggesting a potential upside of 24.55%. Catalent has a consensus target price of $59.83, suggesting a potential downside of 0.14%. Given BioNTech's stronger consensus rating and higher possible upside, equities analysts clearly believe BioNTech is more favorable than Catalent.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioNTech	0 Sell rating(s)	5 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.71
Catalent	0 Sell rating(s)	8 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

BioNTech beats Catalent on 12 of the 19 factors compared between the two stocks.